Valeant Unveils $2B Buyback Plan After Failed Allergan Deal
Canadian drug giant Valeant Pharmaceuticals International Inc. has approved the repurchase of $2 billion in securities, outlining the plans to boost shareholder value Thursday — just days after its $55 billion...To view the full article, register now.
Already a subscriber? Click here to view full article